Feb 6, 2026 07:57AM Polyrizon partners with Clearmind to develop intranasal MEAI formulation

Jan 22, 2026 09:25AM Polyrizon begins usability study for NASARIX allergy blocker

Jan 13, 2026 08:39AM Polyrizon explores investments in defense, aviation and AI sectors

Jan 8, 2026 08:46AM Polyrizon names allergy blocker product NASARIX

Jan 5, 2026 09:07AM Polyrizon reports positive pre-clinical data for PL-14 allergy blocker

Jan 2, 2026 08:32AM Polyrizon submits FDA request for nasal spray amid flu surge

Dec 29, 2025 07:20AM Polyrizon explores real asset investments while advancing medical pipeline

Dec 11, 2025 08:16AM Polyrizon reports positive permeation data for intranasal naloxone hydrogel

Dec 8, 2025 08:56AM Polyrizon completes FDA pre-submission meeting for PL-14 nasal spray

Dec 3, 2025 09:29AM Polyrizon naloxone hydrogel shows improved nasal tissue adhesion in study

Dec 2, 2025 07:55AM Polyrizon completes manufacturing milestone for nasal spray platform

Nov 7, 2025 04:18PM Polyrizon Ltd (PLRZ) files $50M mixed shelf

Nov 6, 2025 08:55AM Polyrizon reports viral blocking efficacy in lab tests for nasal gel

Oct 6, 2025 08:21AM Polyrizon reports positive pre-clinical results for PL-14 allergy blocker

Sep 19, 2025 08:15AM Polyrizon submits FDA pre-submission package for PL-14 allergy blocker

Sep 12, 2025 07:26AM Polyrizon reports successful nasal delivery of allergy blocker in study

Jul 22, 2025 08:32AM Polyrizon reports nasal spray achieves targeted allergen blocking in study

Jul 15, 2025 07:55AM Polyrizon retains NASDAQ listing after hearings panel review

Jun 12, 2025 07:32AM Polyrizon Ltd (PLRZ) Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

May 23, 2025 04:17PM Polyrizon Ltd (PLRZ) receives delisting notice from Nasdaq

May 13, 2025 07:45AM Polyrizon Ltd (PLRZ) Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Apr 25, 2025 07:37AM Polyrizon Ltd (PLRZ) Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 2, 2025 09:06AM Polyrizon (PLRZ) Engages Leading Branding Firm for Strategic Brand Development

Apr 1, 2025 04:09PM Polyrizon Ltd (PLRZ) Closes $17M Private Placement

Mar 31, 2025 09:33AM Polyrizon Ltd (PLRZ) Announces $17M Private Placement at $0.48/unit

Mar 27, 2025 08:25AM Polyrizon Ltd (PLRZ) Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 25, 2025 04:04PM Polyrizon (PLRZ) Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 19, 2025 07:37AM Clearmind Medicine (CMND) to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Mar 14, 2025 08:36AM Polyrizon (PLRZ) signs LOI with psychedelic therapeutics company to develop novel treatments

Mar 13, 2025 07:51AM Polyrizon (PLRZ) Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 10, 2025 07:48AM Polyrizon (PLRZ) Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Jan 30, 2025 05:57AM Polyrizon Ltd (PLRZ) Files Divisional Patent Application for Its Innovative Trap & Target (T&T) Intranasal Drug Delivery Platform

Dec 30, 2024 04:56PM Polyrizon Ltd (PLRZ) Files for 2.42M Share Offering by Selling Stockholders

Dec 19, 2024 07:23AM Polyrizon (PLRZ) Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Dec 13, 2024 06:26AM Polyrizon (PLRZ) Appoints Asaf Azulay as VP of Regulatory Affairs and Quality Assurance

Oct 30, 2024 01:50PM Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Oct 29, 2024 05:59AM Polyrizon (PLRZ) Prices 958.9K Share IPO at $4.38/unit